AstraZeneca Gets Rare Warning Letter Over Breztri Sales Aid; Footnotes Don’t Balance Graphics

 
• By Derrick Gingery
  
Breztri warning letter
OPDP breathes fire on multiple claims in AstraZeneca's sales aid for the COPD treatment Breztri. • Source: Nielsen Hobbs; the Pink Sheet | images from Shutterstock, FDA

More from Marketing & Advertising

More from Compliance